3 completed, 2 active not recruiting, 1 not yet recruiting, 1 recruiting. 4 Phase 2, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Active not recruiting 2, Completed 2 |
| Phase 4 | 2 | Completed 1, Recruiting 1 |
Follow JYNNEOS: new trials by email Literature Review of JYNNEOS trials Research Report on JYNNEOS
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Assessment of Myocarditis After Replication-Deficient Smallpox Immunization JYNNEOS - Myopericarditis, Small Pox | Not yet recruiting | Womack Army Medical Center | 2350 | 2029-03-01 | 2023-12-14 | |
| Comparability Trial of the MVA-BN Vaccine Manufactured in Different Production Cells Jynneos, MVA-BN (Quail) - Monkeypox (Mpox) | Phase 2 | Active not recruiting | Bavarian Nordic | 970 | 2025-10-27 | 2026-04-08 |
| Assessment of Metformin for Restoration of Immune Homeostasis in HIV+ and HIV- Individuals With a History of Injection Drug Use Metformin, Placebo, Jynneos - Systemic Inflammation, Immune Dysregulation | Phase 4 | Recruiting | University of Alabama at Birmingham | 100 | 2025-04-07 | 2026-04-22 |
| Assessment of Safety Profile of MVA-BN Vaccine in the PALM-007 Study in DRC MVA-BN vaccine - Monkeypox | Phase 4 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 500 | 2023-03-23 | 2026-02-12 |
| A Phase 2 Randomized Multisite Trial to Inform Public Health Strategies Involving the Use of MVA-BN Vaccine for Mpox JYNNEOS - Monkeypox | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 450 | 2023-03-22 | 2026-03-27 |
| Trial to Evaluate the Immunogenicity of Dose Reduction Strategies of the MVA-BN Monkeypox Vaccine JYNNEOS - Monkeypox | Phase 2 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 229 | 2022-09-09 | 2026-04-16 |
| Study to Assess the Safety and Immunogenicity of TPOXX® When Administered Orally for 28 Days With JYNNEOS Tecovirimat, Smallpox and Mpox Vaccine, Placebo - Smallpox | Phase 2 | Active not recruiting | SIGA Technologies | 100 | 2022-04-05 | 2026-09-14 |
Mpox, Monkeypox (4) · Smallpox (2)
National Institute of Allergy and Infectious Diseases (NIAID) (3) · Bavarian Nordic (1) · SIGA Technologies (1) · University of Alabama at Birmingham (1) · Womack Army Medical Center (1)
United States (5) · Democratic Republic of the Congo (1) · Puerto Rico (1)
R01DA060692 (1)